DLBCL cells treated with BZ or BAY-11 activated caspase 3 activity after 12 hours of treatment, which can be block with a caspase 3 inhibitor (DVED) but not with a caspase 1 inhibitor (VAD) (Fig. 7E). The gene discussed is CASP3; the disease is diffuse large B-cell lymphoma.